ALEXIS FRASIER: Open Payments
NPI 1043995301 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,593 in 89 payments from 20 companies in 2025. Trend: 2023 $443 · 2024 $910 · 2025 $1,593
Food & beverage: $1,593
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $271 |
| Dexcom, Inc. | 13 | $246 |
| Bayer Healthcare Pharmaceuticals Inc. | 11 | $162 |
| Corcept Therapeutics | 7 | $150 |
| Lilly USA, LLC | 9 | $144 |
| Insulet Corporation | 6 | $117 |
| Abbott Laboratories | 4 | $71 |
| Sequel Med Tech, LLC | 3 | $65 |
| Tandem Diabetes Care, Inc. | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $45 |
Products named: Dexcom G6 Transmitter, Kerendia, Korlym, MOUNJARO, Omnipod, Ozempic, Rybelsus, FREESTYLE LIBRE 3.
Industry payments across LA — which companies pay providers there.
